CytoDyn armed with a "key test" to guide its short-term discussions with the FDA

Dr. Nader Pourhbadan, CEO of CytoDyn Inc. (OTCMKTS: CYDY), told Proactive Investors that the developing biotech company developing leronlimab (PRO 140) as monotherapy for HIV patients has completed a single treatment for HIV.

According to Dr. Pourhbadan, the company performed a diagnostic test, called receptor occupancy test, as a measure to more accurately screen for leronlimab monotherapy.